{"text": "Epstein-Barr virus binding to <extra_id_0> CD21 <extra_id_2> Protein <extra_id_1> activates the initial viral promoter via NF-kappaB induction .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Epstein-Barr virus ( EBV ) , an oncogenic human herpesvirus , binds to and infects normal human B lymphocytes via <extra_id_0> CD21 <extra_id_2> Protein <extra_id_1> , the <extra_id_0> CR2 <extra_id_2> Protein <extra_id_1> complement receptor .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Studies of the mechanisms that enable EBV to infect nonactivated , noncycling B cells provide compelling evidence for a sequence of events in which EBV binding to <extra_id_0> CD21 <extra_id_2> Protein <extra_id_1> on purified resting human B cells rapidly activates the NF-kappaB transcription factor , which , in turn , binds to and mediates transcriptional activation of Wp , the initial viral latent gene promoter .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Thus , EBV binding to its cellular receptor on resting B cells triggers an NF-kappaB - dependent intracellular signaling pathway which is required for infection .", "event": "<extra_id_0> <extra_id_1>"}
